MT. LAUREL, N.J., Feb. 25 /PRNewswire-FirstCall/ -- MedQuist Inc., a leading provider of technology-enabled clinicaldocumentation services, today announced that the United States Bankruptcy Court for the District of Delaware has issued an order approving bidding procedures naming MedQuist, along with CBay Inc., MedQuist's majority
"I am very pleased by today's positive court ruling, as it continues the process forward for MedQuist. We believe the combination of these organizations will result in an even stronger team of talented and skilled professionals to serve Spheris customers and the healthcare market," stated MedQuist CEO Peter Masanotti. He continued, "Our goal is to provide an extensive portfolio of products, technologies and solutions, and a seamless transition that maintains a high level of quality service for all customers. In fact, it is our intent that account representatives, medical transcriptionists, and other service and QA professionals will remain as currently assigned to the Spheris customers. We stand by our commitment to excellence in customer satisfaction and service levels 24 hours a day, every day, and we recognize the critical value of our work as it supports our customers' efforts to provide high quality patient care nationally and internationally."
MedQuist (Nasdaq: MEDQ) is a leading provider of medical transcription services, and a leader in technology-enabled clinical documentation workflow. MedQuist's enterprise solutions -- including mobile voice capture devices, speech recognition, Web-based workflow platforms, and global network of medical editors -- help healthcare facilities improve patient care, increase physician satisfaction, and lower operational costs. For more information, please visit www.medquist.com.
Statements made in this press release that are forward-looking in nature are intended to be "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934 and may involve risks and uncertainties. These statements include, without limitation, statements regarding the terms of the pending transaction and any other statements that are not historical facts. These risks and uncertainties include the timing, receipt of approvals and satisfaction of conditions for the proposed transaction, as well as the risk that another bidder may purchase substantially all of Spheris' assets. Other risks and uncertainties, which are more fully described in documents filed by MedQuist with the Securities and Exchange Commission, including Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, could cause actual results to differ from those contained in the forward-looking statements.
SOURCE MedQuist Inc.
Subscribe to our Free Newsletters!
Sea food allergy is the adverse response of the body''s immune system to the proteins present in ...